Trastuzumab deruxtecan in HER2-positive state-of-the-art bosom cancer cells along with or without human brain metastases: a stage 3b/4 trial

.Nature Medicine, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) treatment of patients along with HER2+ state-of-the-art breast cancer and also energetic or dependable brain metastases presented steady intracranial task as well as systemic efficiency of T-DXd.